ABSTRACT
Background Policies restricting Mohs micrographic surgery (MMS) to only fellowship-trained (FT) surgeons, whether through privileging standards, laboratory-director qualifications, or payer credentialing, would bar residency/practice-trained (R/P-trained) surgeons from MMS. The access consequences have not been quantified.
Objective To quantify the access consequences of restricting MMS to only FT surgeons.
Methods Cross-sectional analysis of all Medicare MMS billers (2020-2024), classified FT or R/P-trained by audited American College of Mohs Surgery directory linkage and linked to Micrographic Dermatologic Surgery (MDS) certification; drive-time simulation of R/P-trained exclusion against the Centers for Medicare & Medicaid Services (CMS) dermatology access standard; fellowship-pipeline replacement modeling; and projection of rural Mohs capacity needed through 2041.
Results R/P-trained surgeons were 45.3% of the 2024 workforce (55.6% MDS-certified), supplied 52.1% of nonmetropolitan MMS volume, and were the only Mohs surgeons in 223 counties. On the specialty’s quality measure, stages per case, the pathways were indistinguishable (median 1.5 in both). Excluding R/P-trained surgeons would put 23.1 million people newly outside the CMS dermatology access standard, with nonmetropolitan drive times rising by 3.2 times the metropolitan increase. R/P-trained surgeons perform 353,736 Medicare cases a year, and the remaining surgeons could not care for all of the displaced patients even at 50% higher caseloads. With R/P-trained surgeons grandfathered, 114 counties would still lose in-county access by 2041. At present, rural access falls 323 surgeons short of the CMS standard. Closing that shortfall by 2041 would take about 77 new rural Mohs surgeons a year, four times today’s entry rate.
Limitations Fee-for-service claims; directory-based classification, audited and adjusted; no clinical outcomes.
Conclusion A fellowship-only restriction would produce large access losses, geographically concentrated and disproportionately rural, and the fellowship pipeline could not replace the excluded surgeons in the counties that would lose them. The workforce loss would affect both metropolitan and nonmetropolitan patients, but with far more severe consequences for nonmetropolitan residents. Access to Mohs surgery rests on both training pathways. Policy should expand every route into Mohs surgery, through more fellowship positions, stronger Mohs training within dermatology residency, and a reopened practice pathway to MDS certification, and should keep laboratory-director and network eligibility keyed to the primary dermatology board certification common to both pathways.
CAPSULE SUMMARY
Privileging, CLIA laboratory-directorship, and payer credentialing policies could restrict Mohs surgery to only fellowship-trained surgeons; the workforce literature had not quantified the access consequences.
Excluding residency/practice-trained surgeons would disproportionately affect nonmetropolitan patients, leave 223 counties without in-county Mohs access, push 23 million people outside the Centers for Medicare & Medicaid Services’ dermatology access standards, and displace roughly 212,000 cases per year that the remaining workforce could not absorb, lengthening waits in urban and rural areas alike; access policy should treat the two pathways as coequal routes into Mohs surgery, as Medicare coverage policy already does.
Competing Interest Statement
Dr. Jeon has no conflicts of interest to declare. Dr. Logue is Founder and President of the Rural Access to Dermatology Society. Dr. Murakawa is Past President of the American Society for Mohs Surgery. Dr. Yu is Chair of the Health Policy Committee and a member of the Board of Directors of the American Society for Mohs Surgery. No author or author's institution received payments or services from a third party in the past 36 months that could be perceived to influence the submitted work. No other competing interests are declared.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available data on physicians in their professional capacity; no patient-level data, biological samples, or human participants were involved, and no private information was accessed. Institutional review board review was not applicable. Sources (all public; dataset versions and retrieval dates are given in the Supplementary Material): CMS Medicare Physician & Other Practitioners Public Use Files, by Provider and Service and by Provider (https://data.cms.gov/provider-summary-by-type-of-service/medicare-physician-other-practitioners); NPPES NPI data dissemination file (https://download.cms.gov/nppes/NPI_Files.html); CMS Doctors and Clinicians national downloadable file (https://data.cms.gov/provider-data/topics/doctors-clinicians); American College of Mohs Surgery public surgeon directory (https://www.mohscollege.org); American Society for Mohs Surgery public surgeon locator (https://www.mohssurgery.org); American Board of Dermatology public diplomate lists and certification verification (https://www.abderm.org); USDA ERS Rural-Urban Continuum Codes (https://www.ers.usda.gov/data-products/rural-urban-continuum-codes); U.S. Census Bureau geography and population estimates (https://www.census.gov); HRSA Health Professional Shortage Area designations (https://data.hrsa.gov); Dartmouth Atlas ZIP-HSA-HRR crosswalk (https://data.dartmouthatlas.org); OpenStreetMap road-network extracts via Geofabrik (https://download.geofabrik.de).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Version 2 revises the presentation of the replacement-capacity result so that the county-level finding is stated first and the aggregate rural-headcount recovery time is reported with its assumptions (no change to the model, inputs, or outputs); adds citation of and comparison with Davis et al., Dermatologic Surgery 2026 (online September 22, 2026), an independent 2023 cross-section that corroborates the rural workforce composition reported here; and adds Figure 7 (the rural Mohs deficit against the CMS access standard and projected demand, 2026-2041) and Table VII (the rural Mohs capacity needed through 2041 to keep status quo access and bring rural residents inside the standard), with a new supplement section describing the need estimate and the demand projection. The text has been condensed to journal length and the abstract restructured. No result of version 1 is changed.
Data availability
This study used only publicly available data; no new data were collected. The primary sources are the CMS Medicare Physician & Other Practitioners Public Use Files (by Provider and Service, and by Provider), NPPES, the American College of Mohs Surgery and American Society for Mohs Surgery public directories, American Board of Dermatology public diplomate lists, the CMS Doctors and Clinicians file, the CMS Medicare Monthly Enrollment and Physician & Other Practitioners by Geography and Service datasets, USDA ERS Rural-Urban Continuum Codes, U.S. Census geography and population estimates, published county population projections by age (Hauer 2019), HRSA HPSA designations, the Dartmouth Atlas ZIP–HSA–HRR crosswalk, and OpenStreetMap/Geofabrik road networks, each cited with dataset versions and retrieval dates in the Supplementary Material, which also describes the analytic steps and parameters. Individual physician-level records derived from these sources are not redistributed. Aggregate result tables (county- and state-level) are available from the corresponding author on reasonable request.





